Abstract:BACKGROUND:Products of the SOX gene family play important roles in the life process. One of the members, SOX7, is associated with the development of a variety of cancers as a tumor suppression factor, but its relevance with ovarian cancer was unclear. In this study, we investigated the involvement of SOX7 in the progression and prognosis of epithelial ovarian cancer (EOC) and the involved mechanisms.METHODS:Expression profiles in two independent microarray data sets were analyzed for SOX7 between malignant and normal tissues. The expression levels of SOX7 in EOC, borderline ovarian tumors and normal ovarian tissues were measured by immunohistochemistry. We also measured levels of COX2 and cyclin-D1 to examine their possible involvement in the same signal transduction pathway as SOX7.RESULTS:The expression of SOX7 was significantly reduced in ovarian cancer tissues compared with normal controls, strongly indicating that SOX7 might be a negative regulator in the Wnt/β-catenin pathway in ovarian cancer. By immunohistochemistry staining, the protein expression of SOX7 showed a consistent trend with that of the gene expression microarray analysis. By contrast, the protein expression level of COX2 and cyclin-D1 increased as the tumor malignancy progressed, suggesting that SOX7 may function through the Wnt/β-catenin signaling pathway as a tumor suppressor. In comparison between the protein expression levels of SOX7 with pathological features of the cancer, we found that SOX7 was down-regulated mainly in serous cystadenocarcinoma and advanced stages of the cancers.CONCLUSIONS:The expression of SOX7 correlates with tumor progression as a tumor suppressor, possibly through the Wnt/β-catenin signaling pathway in ovarian cancers, suggesting that SOX7 may be a promising prognostic marker.

SOX7 is associated with the suppression of human glioma by HMG-box dependent regulation of Wnt/β-catenin signaling

SOX9+ malignant cells define a poor prognosis subtype of Glioma with tumor-associated macrophage recruitment

SOX7——A Novel Tumor Suppressor

SOX7 Modulates the Progression of Hepatoblastoma Through the Regulation of Wnt/β-catenin Signaling Pathway.

SOX7: from a developmental regulator to an emerging tumor suppressor.

SOX15 Exerts Antitumor Function in Glioma by Inhibiting Cell Proliferation and Invasion Via Downregulation of Wnt/β-catenin Signaling.

SOX9 Overexpression Promotes Glioma Metastasis via Wnt/β-Catenin Signaling

SOX7 Co-Regulates Wnt/β-catenin Signaling with Axin-2: Both Expressed at Low Levels in Breast Cancer

Long Noncoding RNA AB073614 Promotes the Malignance of Glioma by Activating Wnt/β-catenin Signaling Through Downregulating SOX7.

The Suppressive Role of SOX7 in Hepatocarcinogenesis

SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.

Reduced Expression of SOX7 in Ovarian Cancer: a Novel Tumor Suppressor Through the Wnt/β-catenin Signaling Pathway

Decreased Expression Of Sox7 Correlates With The Upregulation Of The Wnt/Beta-Catenin Signaling Pathway And The Poor Survival Of Gastric Cancer Patients

Novel role of sex-determining region Y-box 7 (SOX7) in tumor biology and cardiovascular developmental biology

SOX7 is Down-Regulated in Lung Cancer

Gene Expression Profile Analysis of U251 Glioma Cells with Shrna-Mediated SOX9 Knockdown.

Analysis of SOX9 Expression in Colorectal Cancer.

SOX7 Target Genes and Their Contribution to Its Tumor Suppressive Function.

SOX17 Antagonizes WNT/β-catenin Signaling Pathway in Hepatocellular Carcinoma

The Regulation of SOX7 and Its Tumor Suppressive Role in Breast Cancer.

SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis